Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis

被引:1
作者
Pan, Kunming [1 ]
Li, Ranyi [1 ]
Li, Yanli [1 ]
Ding, Xiaoqiang [2 ]
Li, Xiaoyu [1 ]
Lv, Qianzhou [1 ]
机构
[1] Fudan Univ, ZhongShan Hosp, Dept Pharm, 180 Fenglin Rd, Shanghai, Peoples R China
[2] Fudan Univ, ZhongShan Hosp, Dept Nephropathy, 180 Fenglin Rd, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
PATIENTS RECEIVING VANCOMYCIN; PROPENSITY SCORE METHODS; ACUTE-RENAL-FAILURE; CONCOMITANT VANCOMYCIN; INDUCED NEPHROTOXICITY; HOSPITALIZED-PATIENTS; COMBINATION THERAPY; ILL PATIENTS; TAZOBACTAM; CEFEPIME;
D O I
10.1093/jac/dkae410
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To explore whether vancomycin plus piperacillin/tazobactam actually increases nephrotoxicity compared with other anti-pseudomonal beta-lactams (BLs). Methods: PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang and VIP were searched from inception to October 2023. The primary outcomes were acute kidney injury (AKI) as defined as acute increase in serum creatinine of 0.3 mg/dL or 50% and severe Stage 2-3 AKI. Results: We included 70 studies (76 638 patients). Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than vancomycin plus cefepime (OR 2.55, 95% CI 2-3.28), vancomycin plus meropenem (OR 2.26, 95% CI 1.71-3.02) and vancomycin plus other uncommonly used BLs (OR 2.47, 95% CI 1.87-3.29). Also, vancomycin +piperacillin/tazobactam was associated with significantly higher Stage 2-3 AKI risk than vancomycin +cefepime (OR 2.22, 95% CI 1.34-3.62), vancomycin +meropenem (OR1.96, 95% CI 1.22-3.25) and vancomycin + uncommonly used BLs (OR 2.81, 95% CI 1.66- 4.91). Vancomycin plus piperacillin/tazobactam did not result in a significant difference in the incidence of receiving dialysis treatment, mortality, length of stay and time to AKI. Subgroup analyses of studies conducting propensity score matching demonstrated vancomycin +piperacillin/tazobactam was associated with significantly higher AKI rates than vancomycin +cefepime (OR 2.19, 95% CI 1.38-3.47) and vancomycin + meropenem (OR 1.38, 95% CI. 1.18-1.60). Subgroup analysis of critically ill patients and children indicated that vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates. Conclusions: Vancomycin +piperacillin/tazobactam significantly increased the risk of AKI and severe Stage 2-3 AKI compared with vancomycin plus other BLs. More prospective studies are needed.
引用
收藏
页码:47 / 58
页数:12
相关论文
共 99 条
[1]   Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital [J].
Al Nuhait, Mohammed ;
Abu Esba, Laila C. ;
Al Harbi, Khalid ;
Al Meshary, Meshary ;
Bustami, Rami T. .
INTERNATIONAL JOURNAL OF PEDIATRICS, 2018, 2018
[2]   Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or with meropenem [J].
Al Yami, Majed S. .
JOURNAL OF INFECTION AND PUBLIC HEALTH, 2017, 10 (06) :770-773
[3]   Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam [J].
Alosaimy, Sara ;
Lagnf, Abdalhamid M. ;
Hobbs, Athena L., V ;
Mubarez, Musa ;
Kufel, Wesley D. ;
Morrisette, Taylor ;
Polisetty, Radhika S. ;
Li, David ;
Veve, Michael P. ;
Simon, Sam P. ;
Truong, James ;
Finch, Natalie ;
Venugopalan, Veena ;
Rico, Matthew ;
Amaya, Lee ;
Yost, Christine ;
Cubillos, Ashley ;
Chandler, Elisabeth ;
Patch, Megan ;
Smith, Ian Murphy Kelsey ;
Biagi, Mark ;
Wrin, Justin ;
Moore, W. Justin ;
Molina, Kyle C. ;
Rebold, Nicholas ;
Holger, Dana ;
Coyne, Ashlan J. Kunz ;
Jorgensen, Sarah ;
Witucki, Paige ;
Tran, Nikki N. ;
Davis, Susan L. ;
Sakoulas, George ;
Rybak, Michael J. .
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) :E1444-E1455
[4]   Acute Kidney Injury in Pediatric Patients Treated with Vancomycin and Piperacillin-Tazobactam Versus Vancomycin and Cefotaxime: A Single-center Study [J].
Alqurashi, Rewaa ;
Batwa, Mawaddah ;
Alghamdi, Bashayer ;
Aljohani, Saja ;
Zaher, Nada ;
Alzahrani, Amal ;
Aldigs, Eman ;
Safdar, Osama .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (01)
[5]   Comparative Risk of Acute Kidney Injury Following Concurrent Administration of Vancomycin with Piperacillin/Tazobactam or Meropenem: A Systematic Review and Meta-Analysis of Observational Studies [J].
Alshehri, Abdulmajeed M. ;
Alzahrani, Mohammed Y. ;
Abujamal, Mohammed A. ;
Abdalla, Mariam H. ;
Alowais, Shuroug A. ;
Alfayez, Osamah M. ;
Alyami, Majed S. ;
Almutairi, Abdulaali R. ;
Almohammed, Omar A. .
ANTIBIOTICS-BASEL, 2022, 11 (04)
[6]  
Anderson CW, 2017, MIL MED, V182, pE1773, DOI [10.7205/MILMED-D-16-00197, 10.7205/milmed-d-16-00197]
[7]   Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury [J].
Aslan, Abdullah Tarik ;
Pashayev, Tural ;
Dag, Osman ;
Akova, Murat .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021, 40 (09) :1953-1961
[8]   A Tutorial and Case Study in Propensity Score Analysis: An Application to Estimating the Effect of In-Hospital Smoking Cessation Counseling on Mortality [J].
Austin, Peter C. .
MULTIVARIATE BEHAVIORAL RESEARCH, 2011, 46 (01) :119-151
[9]   Piperacillin-Tazobactam Added to Vancomycin Increases Risk for Acute Kidney Injury: Fact or Fiction? [J].
Avedissian, Sean N. ;
Pais, Gwendolyn M. ;
Liu, Jiajun ;
Rhodes, Nathaniel J. ;
Scheetz, Marc H. .
CLINICAL INFECTIOUS DISEASES, 2020, 71 (02) :426-432
[10]   Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern? [J].
Balci, Cafer ;
Uzun, Omrum ;
Arici, Mustafa ;
Hayran, Sibel Ascioglu ;
Yuce, Deniz ;
Unal, Serhat .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2018, 52 (02) :180-184